Estrella Immunopharma (ESLA) Liabilities and Shareholders Equity (2021 - 2026)

Estrella Immunopharma (ESLA) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 49.62% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $13.3 million (down 3.17% YoY), while the FY2025 annual figure was $3.2 million, up 1.15% from the prior year.
• Liabilities and Shareholders Equity advanced to $3.7 million in Q1 2026 per ESLA's latest filing, from $3.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $45.6 million in Q3 2022 and bottomed at $2.4 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $13.6 million across 5 years, with a median of $4.5 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 93.33% — and 2026, when it soared 49.62%.
• Estrella Immunopharma's Liabilities and Shareholders Equity stood at $9.7 million in 2022, then dropped by 2.84% to $9.4 million in 2023, then sank by 66.75% to $3.1 million in 2024, then rose by 1.15% to $3.2 million in 2025, then increased by 15.12% to $3.7 million in 2026.
• Business Quant data shows ESLA's Liabilities and Shareholders Equity at $3.7 million in Q1 2026, $3.2 million in Q4 2025, and $3.5 million in Q3 2025.